Matthias Pinter1,2, Arndt Weinmann3,4,5, Marcus-Alexander Wörns3,4, Florian Hucke1,6, Simona Bota1,6, Jens U Marquardt3,4, Dan G Duda2, Rakesh K Jain2, Peter R Galle3,4, Michael Trauner1, Markus Peck-Radosavljevic1,6, Wolfgang Sieghart1. 1. Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. 2. Department of Radiation Oncology, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA. 3. Department of Medicine I, University Medical Center Johannes Gutenberg University, Mainz, Germany. 4. Cirrhosis Center Mainz (CCM), University Medical Center Johannes Gutenberg University, Mainz, Germany. 5. Clinical Registry Unit (CRU), University Medical Center Johannes Gutenberg University, Mainz, Germany. 6. Department of Gastroenterology & Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Abstract
BACKGROUND: Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies. OBJECTIVE: The objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC). METHODS: Patients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses. RESULTS: In the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p = 0.014) and remained a significant prognostic factor upon multivariate analysis (HR = 0.6; 95% CI 0.4-0.9; p = 0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5 mo) compared to those treated with either sorafenib (10.9 mo) or RASi (9.7 mo) alone (p = 0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n = 76). CONCLUSION: RAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.
BACKGROUND: Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies. OBJECTIVE: The objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC). METHODS: Patients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses. RESULTS: In the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p = 0.014) and remained a significant prognostic factor upon multivariate analysis (HR = 0.6; 95% CI 0.4-0.9; p = 0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5 mo) compared to those treated with either sorafenib (10.9 mo) or RASi (9.7 mo) alone (p = 0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n = 76). CONCLUSION: RAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.
Authors: H Yoshiji; S Kuriyama; M Kawata; J Yoshii; Y Ikenaka; R Noguchi; T Nakatani; H Tsujinoue; H Fukui Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: Florian Hucke; Wolfgang Sieghart; Maximilian Schöniger-Hekele; Markus Peck-Radosavljevic; Christian Müller Journal: Wien Klin Wochenschr Date: 2011-07-29 Impact factor: 1.704
Authors: Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike Journal: Br J Cancer Date: 2010-10-26 Impact factor: 7.640
Authors: Yunching Chen; Yuhui Huang; Thomas Reiberger; Annique M Duyverman; Peigen Huang; Rekha Samuel; Lotte Hiddingh; Sylvie Roberge; Christina Koppel; Gregory Y Lauwers; Andrew X Zhu; Rakesh K Jain; Dan G Duda Journal: Hepatology Date: 2014-02-18 Impact factor: 17.425
Authors: Georgina E Riddiough; Katrina A Walsh; Theodora Fifis; Georgios Kastrappis; Bang M Tran; Elizabeth Vincan; Vijayaragavan Muralidharan; Christopher Christophi; Claire L Gordon; Marcos V Perini Journal: Int J Mol Sci Date: 2022-05-09 Impact factor: 6.208